drugset / Trial / NCT06354257

A Study to Investigate the Pharmacokinetics of a Combined Oral Contraceptive When Given Alone and in Combination With GSK3036656 in Female Participants of Non-childbearing Potential Aged 18 to 65 Years of Age

NCT06354257

Phase 1 Completed 20 enrolled GlaxoSmithKline
Non-randomizedSequentialOpen-labelPrevention

Summary

The purpose of this study is to provide data showing if there are any effects of GSK3036656 on a combined oral contraceptive containing Ethinyl Estradiol (EE) and Levonorgestrel (LNG), which will help inform future studies on suitable contraceptive measures to be used.

Timeline

Start
2024-04-05
Primary completion
2024-07-01
Completion
2024-07-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Ganfeborole Small molecule 20 mg
Subject Microgynon Unknown 0.03 mg Oral
Subject Microgynon Unknown 0.15 mg Oral

Indications